Press Resease

Global Oncology Based In-Vivo CRO Market - By Indication (Solid Tumors, Blood Cancer, Patient-Derived Xenograft, Syngeneic Model, Xenograft, and Others), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025

Published Date: 19-Jan-2021 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2982 Status : Published

The global Oncology Based In-vivo CRO market, which accrued revenue worth nearly 2 (USD Billion) in 2018 and is slated to garner earnings worth 6 (USD Billion) by 2025, is set to grow at a CAGR of 7.7% during the period from 2019 to 2025.

Description

The global Oncology Based In-vivo CRO market, which accrued revenue worth nearly 2 (USD Billion) in 2018 and is slated to garner earnings worth 6 (USD Billion) by 2025, is set to grow at a CAGR of 7.7% during the period from 2019 to 2025. The report offers valuation and analysis of the Oncology Based In-vivo CRO market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, restraints, revenue estimates, avenues, current & emerging trends, and industry-validated market information. The report offers historical data from 2015 to 2018 along with a forecast from 2019 to 2025 based on value (USD Billion).

Introduction

Oncology models based on Immuno-deficient mice clinical trials are used for carrying out oncology research on human subjects across the globe. Apart from this, introduction of new models such as transgenic mice model of cancer provide the potential of creating more predictive prototypes for cancer. Increase in the cancer cases and huge government investment on oncology research & development activities along with high allocation of funds for CRO researching on cancer drug therapies will prompt the growth of the oncology based in-vivo CRO industry over the forecast timeframe.

Market Growth Dynamics

A surge in the aging population prone to chronic diseases such as cancer is likely to define the expansion of oncology based in-vivo CRO industry over the forecast timeframe. Rise in the innovations in genetic engineering along with growing focus on oncogene study will promulgate the oncology based in-vivo CRO market size.  A prominent increase in the particular treatments for cancer along with easy access to large proportion of medicines along with utilization of oncology based in-vivo CRO for finding new diagnosis & treatment for cancer will prompt the business growth.

Furthermore, massive use of smartphones in healthcare and pharma sectors along with growing internet & social media penetration across the globe is expected to facilitate the emergence of oncology based in-vivo CRO industry over the forecast timeframe. Apparently, the approval of generic medicines by organizations such as U.S. FDA and launch of biosimilars has encouraged the pharma firms to take support of CROs for cancer research & drug development. Such moves will create a strong platform for the growth of the oncology based in-vivo CRO industry over the assessment period.

North America To Contribute Majorly Towards Oncology Based In-Vivo CRO Market Revenue By 2025

The expansion of oncology based in-vivo CRO industry in North America over the assessment timeline is credited to large allocation of funds for cancer research activities in the U.S. Apart from this, presence of mammoth life science & pharma firms in the region and their active involvement in drug development process for cancer treatment will promote the market growth in the sub-continent over the years ahead. Easy availability of strong healthcare facilities in the countries like Canada and the U.S. along with massive requirement of aid from CROs to reputed pharma, healthcare & medical devices, and biotech firms for conducting research pertaining to cancer treatment will provide impetus to the growth of the business in the sub-continent.

Major participants in the industry include Living Tumor Laboratory; EVOTEC; Taconic Biosciences; Charles River Laboratory; Xentech; The Jackson Laboratory; Eurofins Scientific; MI Bioresearch, Inc.; Crown Bioscience; ICON Plc.; Covance; Wuxi AppTec; and Champion Oncology, Inc.

The global oncology based in-vivo CRO market is segmented as follows:

By indication:

  • Blood cancer
  • Syngeneic model
  • Solid tumors
  • PDX (Patient-Derived Xenograft)
  • Xenograft
  • Other

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodulogy
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodulogy
  • Chapter 2. Executive Summary
    • 2.1. Onculogy Based In-Vivo CRO Market, 2015–2025 (USD Billion)
    • 2.2. Onculogy Based In-Vivo CRO Market: Snapshot
  • Chapter 3. Global Onculogy Based In-Vivo CRO Market– Industry Analysis
    • 3.1. Onculogy Based In-Vivo CRO Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. A surge in the aging population prone to chronic diseases such as cancer is likely to define the expansion of onculogy based in-vivo CRO industry over the forecast timeframe.
      • 3.2.2. Approval of generic medicines by organizations such as U.S. FDA and launch of biosimilars has encouraged the pharma firms to take support of CROs for cancer research & drug development. Such moves will create a strong platform for the growth of the onculogy based in-vivo CRO industry over the assessment period.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Indication
  • Chapter 4. Global Onculogy Based In-Vivo CRO Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Onculogy Based In-Vivo CRO Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Onculogy Based In-Vivo CRO Market– Indication Analysis
    • 5.1. Global Onculogy Based In-Vivo CRO Market overview: By Indication
      • 5.1.1. Global Onculogy Based In-Vivo CRO Market share, By Indication , 2019 and 2025
    • 5.2. Sulid Tumors
      • 5.2.1. Global Onculogy Based In-Vivo CRO Market By Sulid Tumors , 2015–2025 (USD Billion)
    • 5.3. Blood Cancer
      • 5.3.1. Global Onculogy Based In-Vivo CRO Market By Blood Cancer, 2015–2025 (USD Billion)
    • 5.4. Patient-Derived Xenograft
      • 5.4.1. Global Onculogy Based In-Vivo CRO Market By Patient-Derived Xenograft , 2015–2025 (USD Billion)
    • 5.5. Syngeneic Model
      • 5.5.1. Global Onculogy Based In-Vivo CRO Market By Syngeneic Model, 2015–2025 (USD Billion)
    • 5.6. Xenograft
      • 5.6.1. Global Onculogy Based In-Vivo CRO Market By Xenograft, 2015–2025 (USD Billion)
    • 5.7. Others
      • 5.7.1. Global Onculogy Based In-Vivo CRO Market By Others, 2015–2025 (USD Billion)
  • Chapter 6. Company Profiles
    • 6.1. Charles River Laboratory
      • 6.1.1. Overview
      • 6.1.2. Financials
      • 6.1.3. Product Portfulio
      • 6.1.4. Business Strategy
      • 6.1.5. Recent Developments
    • 6.2. Eurofins Scientific
      • 6.2.1. Overview
      • 6.2.2. Financials
      • 6.2.3. Product Portfulio
      • 6.2.4. Business Strategy
      • 6.2.5. Recent Developments
    • 6.3. Crown Bioscience
      • 6.3.1. Overview
      • 6.3.2. Financials
      • 6.3.3. Product Portfulio
      • 6.3.4. Business Strategy
      • 6.3.5. Recent Developments
    • 6.4. ICON Plc.
      • 6.4.1. Overview
      • 6.4.2. Financials
      • 6.4.3. Product Portfulio
      • 6.4.4. Business Strategy
      • 6.4.5. Recent Developments
    • 6.5. The Jackson Laboratory
      • 6.5.1. Overview
      • 6.5.2. Financials
      • 6.5.3. Product Portfulio
      • 6.5.4. Business Strategy
      • 6.5.5. Recent Development
    • 6.6. EVOTEC
      • 6.6.1. Overview
      • 6.6.2. Financials
      • 6.6.3. Product Portfulio
      • 6.6.4. Business Strategy
      • 6.6.5. Recent Development
    • 6.7. Covance
      • 6.7.1. Overview
      • 6.7.2. Financials
      • 6.7.3. Product Portfulio
      • 6.7.4. Business Strategy
      • 6.7.5. Recent Development
    • 6.8. Taconic Biosciences
      • 6.8.1. Overview
      • 6.8.2. Financials
      • 6.8.3. Product Portfulio
      • 6.8.4. Business Strategy
      • 6.8.5. Recent Development
    • 6.9. Wuxi AppTec
      • 6.9.1. Overview
      • 6.9.2. Financials
      • 6.9.3. Product Portfulio
      • 6.9.4. Business Strategy
      • 6.9.5. Recent Development
    • 6.10. Living Tumor Laboratory
      • 6.10.1. Overview
      • 6.10.2. Financials
      • 6.10.3. Product Portfulio
      • 6.10.4. Business Strategy
      • 6.10.5. Recent Development
    • 6.11. MI Bioresearch, Inc.
      • 6.11.1. Overview
      • 6.11.2. Financials
      • 6.11.3. Product Portfulio
      • 6.11.4. Business Strategy
      • 6.11.5. Recent Development
    • 6.12. Xentech
      • 6.12.1. Overview
      • 6.12.2. Financials
      • 6.12.3. Product Portfulio
      • 6.12.4. Business Strategy
      • 6.12.5. Recent Development
    • 6.13. Champion Onculogy, Inc.
      • 6.13.1. Overview
      • 6.13.2. Financials
      • 6.13.3. Product Portfulio
      • 6.13.4. Business Strategy
      • 6.13.5. Recent Development

Methodology


Frequently Asked Questions

A surge in the aging population prone to chronic diseases such as cancer is likely to define the expansion of oncology based in-vivo CRO industry over the forecast timeframe. Rise in the innovations in genetic engineering along with growing focus on oncogene study will promulgate the oncology based in-vivo CRO market size.  A prominent increase in the particular treatments for cancer along with easy access to large proportion of medicines along with utilization of oncology based in-vivo CRO for finding new diagnosis & treatment for cancer will prompt the business growth.

Furthermore, massive use of smartphones in healthcare and pharma sectors along with growing internet & social media penetration across the globe is expected to facilitate the emergence of oncology based in-vivo CRO industry over the forecast timeframe.

According to Zion market research, the global Oncology Based In-vivo CRO market, which accrued revenue worth nearly 2 (USD Billion) in 2018 and slated to garner earnings worth 6 (USD Billion) by 2025, is set to grow at a CAGR of 7.7% during the period from 2019 to 2025.

North America is likely to make noteworthy contributions towards overall market revenue during 2019-2025. The surge in the expansion of market in the sub-continent over the estimated timespan is due to large allocation of funds for cancer research activities in the U.S. Apart from this, presence of mammoth life science & pharma firms in the region and their active involvement in drug development process for cancer treatment will promote the market growth in the sub-continent over the years ahead. Easy availability of strong healthcare facilities in the countries like Canada and the U.S. along with massive requirement of aid from CROs to reputed pharma, healthcare & medical devices, and biotech firms for conducting research pertaining to cancer treatment will provide impetus to the growth of the business in the sub-continent.

The key players profiled in the report include Living Tumor Laboratory; EVOTEC; Taconic Biosciences; Charles River Laboratory; Xentech; The Jackson Laboratory; Eurofins Scientific; MI Bioresearch, Inc.; Crown Bioscience; ICON Plc.; Covance; Wuxi AppTec; and Champion Oncology, Inc.
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com